About SynOx Therapeutics Limited
SynOx Therapeutics Ltd is solely focused on developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies.
At SynOx, we are committed to raising awareness of this disease, understanding the challenges that contribute to TGCT, and addressing the needs of patients suffering from TGCT.
We would like to add a poster to our LinkedIn page, to raise awareness.